Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
